03/27/2020

IBRANCE® (palbociclib) is transitioning from capsules to tablets

Important safety information and full prescribing information for capsules

Pfizer Oncology is pleased to announce that the new film-coated tablets may be taken with or without food and will be dispensed in blister packs (rather than bottles). The blister packs are designed to enable patients to track where they are in their treatment cycle. The tablet formulation is bioequivalent to the capsule formulation. There is no change to the active ingredient, available dosage strengths or dosing schedule.

IBRANCE is indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with:

• an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or

• fulvestrant in patients with disease progression following endocrine therapy

A trade sheet for the tablet formulation (including the IBRANCE tablet full Prescribing Information): CLICK HERE

Frequently Asked Questions About the Transition From Capsules to Tablets: CLICK HERE

Important Safety Information: CLICK HERE